Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
Price : $35 *
At a glance
- Drugs Icotinib (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 14 Jul 2015 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018 as reported by ClinicalTrials.gov record.
- 14 Jul 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 26 Jun 2014 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.